Blockage of the NLRP3 inflammasome/IL-1β pathway by MCC950 improved anti-tumour immune responses in an HNSCC mouse model120 and blockade of the IL-1β pathway by biopharmaceutical drug anakinra has overcome erlotinib resistance in HNSCC xenografts125. This evidence concerns the gene NLRP3 and head and neck squamous cell carcinoma.